US OptionsDetailed Quotes
XFOR240719C500
- 0.06
- -0.08-57.14%
15min DelayClose Jul 8 15:59 ET
0.15High0.06Low
0.14Open0.14Pre Close3 Volume197 Open Interest0.50Strike Price35.00Turnover128.24%IV-3.61%PremiumJul 19, 2024Expiry Date0.08Intrinsic Value100Multiplier11DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.7849Delta2.2358Gamma5.81Leverage Ratio-0.0018Theta0.0001Rho4.56Eff Leverage0.0003Vega
X4 Pharmaceuticals Stock Discussion
holy shit
X4 Pharmaceuticals to Host Virtual Investor Event on June 27, 2024 to Review New Mavorixafor Clinical Data from Ongoing Phase 2 Trial in Chronic Neutropenia
X4 Pharmaceuticals (Nasdaq: XFOR) will host a virtual investor event on June 27, 2024, at 8:00 AM ET to present new interim results from a Phase 2 clinical trial on mavorixafor for treating chronic neutropenia (CN).
The webcast will showcase hematological data from at least 15 participants, treated either wi...
$Iovance Biotherapeutics(IOVA.US)$ Phase 2
$Supernus Pharmaceuticals(SUPN.US)$ Phase 2a
$BRANDES INTERNATIONAL ETF(BINV.US)$ Phase 2a
$MorphoSys(MOR.US)$ Phase 2
$Nuvation Bio(NUVB.US)$ Phase 2
$ALX Oncology(ALXO.US)$ Phase 2
$BioXcel Therapeutics(BTAI.US)$ Phase 2
$Purple Biotech(PPBT.US)$ Phase 2
$Arcus Biosciences(RCUS.US)$ Phase 2
$Medicenna Therapeutics(MDNAF.US)$ Phase 2b
$Affimed NV(AFMD.US)$ Phase 2
$Barinthus Biotherapeutics(BRNS.US)$ Phase 2b...
No comment yet